CA19‐9 is a significant prognostic factor in stage III gastric cancer patients undergoing radical gastrectomy

Xiao Ma,Xiaohua Zhou,Jiaxuan Guo,Xinyu Feng,Mengmeng Zhao,Peng Zhang,Chong Zhang,Shuai Gong,Nai Wu,Yi Zhang,Xiuzhong Zhang,Zeqiang Ren,Pengbo Zhang
DOI: https://doi.org/10.1186/s12893-024-02324-3
2024-01-24
BMC Surgery
Abstract:Due to the great heterogeneity of gastric cancer (GC), the prognosis of patients within a stage is very different. Therefore, it is necessary to identify the high risk factors for postoperative recurrence and metastasis and take appropriate therapeutic strategies to improve the prognosis of patients. In this study, we aimed to explore the prognostic significance of preoperative and postoperative serum carcinoembryonic antigen (CEA), carbohydrate antigen 19 − 9 (CA19-9) and carbohydrate antigen 72 − 4 (CA72-4) in patients with stage I, II and III GC who underwent radical gastrectomy.
surgery
What problem does this paper attempt to address?
This paper aims to explore the prognostic significance of preoperative and postoperative serum carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), and carbohydrate antigen 72-4 (CA72-4) in patients with stage I, II, and III gastric cancer, particularly the relationship of these markers with recurrence and metastasis after radical gastrectomy. The study found that in stage III gastric cancer patients, CA19-9 levels are an independent risk factor and can be used to predict patients' recurrence-free survival (RFS) and overall survival (OS). Additionally, the study indicates that adjuvant chemotherapy has a protective effect on OS. Therefore, this research mainly focuses on how to use these tumor markers to better assess and manage the prognosis of gastric cancer patients.